These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 25315248)

  • 1. [Antiplatelet therapy in acute coronary syndrome. Prehospital phase: nothing, aspirin or what?].
    Bauer T; Hamm C
    Herz; 2014 Nov; 39(7):803-7. PubMed ID: 25315248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiplatelet effect of ticagrelor compared to tirofiban in non-ST-segment elevation ACS patients undergoing PCI. The result of the TE-CLOT trial.
    Kim JS; Han DC; Jeong YH; Park DW; Sohn CB; Hwang KW; Lee SH; Choi JH; Chon MK; Lee SY; Hwang J; Kim IS; Lee SM; Han J; Noh M; Kim CH; Chun KJ; Park YH; Kim JH
    Thromb Haemost; 2016 Jan; 115(1):213-21. PubMed ID: 26581884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Antiplatelet therapy after acute coronary syndrome. Therapeutic strategies and treatment duration].
    Olivier CB; Diehl P; Bode C; Moser M
    Herz; 2014 Nov; 39(7):808-13. PubMed ID: 25359405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical pharmacology of current antiplatelet drugs].
    Trenk D; Nührenberg T; Stratz C; Valina CM; Hochholzer W
    Herz; 2014 Nov; 39(7):790-7. PubMed ID: 25267101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
    Harrington RA; Becker RC; Cannon CP; Gutterman D; Lincoff AM; Popma JJ; Steg G; Guyatt GH; Goodman SG
    Chest; 2008 Jun; 133(6 Suppl):670S-707S. PubMed ID: 18574276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triple antiplatelet therapy in acute coronary syndromes.
    Valgimigli M; Minarelli M
    Drugs; 2011 Sep; 71(13):1703-19. PubMed ID: 21902293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The emerging role of platelet glycoprotein IIb/IIIa inhibitors in managing high-risk patients with non-ST segment elevation acute coronary syndromes.
    Bolognese L
    Curr Med Res Opin; 2007 Jun; 23(6):1217-26. PubMed ID: 17559721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of one-month versus twelve-month dual antiplatelet therapy after implantation of drug-eluting stents guided by either intravascular ultrasound or angiography in patients with acute coronary syndrome: rationale and design of prospective, multicenter, randomized, controlled IVUS-ACS and ULTIMATE-DAPT trial.
    Ge Z; Gao XF; Kan J; Kong XQ; Zuo GF; Ye F; Tian NL; Lin S; Liu ZZ; Shao YB; He YQ; Wen SY; Yang Q; Xia Y; Wang ZZ; Xiao PX; Li F; Zeng HS; Yang S; Wang Y; Tao L; Gao DS; Qu H; Qian XS; Han YL; Chen F; Zhang JJ; Chen SL
    Am Heart J; 2021 Jun; 236():49-58. PubMed ID: 33621541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both?
    Silva MA; Donovan JL; Gandhi PJ; Volturo GA
    Vasc Health Risk Manag; 2006; 2(1):39-48. PubMed ID: 17319468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiplatelet intervention in acute coronary syndrome.
    Arora RR; Rai F
    Am J Ther; 2009; 16(5):e29-40. PubMed ID: 19092648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS.
    Baber U; Dangas G; Angiolillo DJ; Cohen DJ; Sharma SK; Nicolas J; Briguori C; Cha JY; Collier T; Dudek D; Džavik V; Escaned J; Gil R; Gurbel P; Hamm CW; Henry T; Huber K; Kastrati A; Kaul U; Kornowski R; Krucoff M; Kunadian V; Marx SO; Mehta S; Moliterno D; Ohman EM; Oldroyd K; Sardella G; Sartori S; Shlofmitz R; Steg PG; Weisz G; Witzenbichler B; Han YL; Pocock S; Gibson CM; Mehran R
    Eur Heart J; 2020 Oct; 41(37):3533-3545. PubMed ID: 33085967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy.
    Tanguay JF; Bell AD; Ackman ML; Bauer RD; Cartier R; Chan WS; Douketis J; Roussin A; Schnell G; Verma S; Wong G; Mehta SR;
    Can J Cardiol; 2013 Nov; 29(11):1334-45. PubMed ID: 23978596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiplatelet strategies: evaluating their current role in the setting of acute coronary syndromes.
    Braunwald E; Angiolillo D; Bates E; Berger PB; Bhatt D; Cannon CP; Furman MI; Gurbel P; Michelson AD; Peterson E; Wiviott S
    Clin Cardiol; 2008 Mar; 31(3 Suppl 1):I2-9. PubMed ID: 18481818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upstream use of small-molecule glycoprotein iib/iiia inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systematic overview of randomized clinical trials.
    Tricoci P; Newby LK; Hasselblad V; Kong DF; Giugliano RP; White HD; Théroux P; Stone GW; Moliterno DJ; Van de Werf F; Armstrong PW; Prabhakaran D; Rasoul S; Bolognese L; Durand E; Braunwald E; Califf RM; Harrington RA
    Circ Cardiovasc Qual Outcomes; 2011 Jul; 4(4):448-58. PubMed ID: 21712522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost Effectiveness of Antiplatelet and Antithrombotic Therapy in the Setting of Acute Coronary Syndrome: Current Perspective and Literature Review.
    Fanari Z; Weiss S; Weintraub WS
    Am J Cardiovasc Drugs; 2015 Dec; 15(6):415-27. PubMed ID: 26068886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Approach to non-ST-segment elevation acute coronary syndrome in the emergency department: risk stratification and treatment strategies.
    Lefebvre CW; Hoekstra J
    Hosp Pract (1995); 2010 Apr; 38(2):40-9. PubMed ID: 20469612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing antithrombotic therapy in patients with non-ST-segment elevation acute coronary syndrome.
    Dobesh PP; Phillips KW; Haines ST
    Am J Health Syst Pharm; 2008 Aug; 65(15 Suppl 7):S22-8. PubMed ID: 18653821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ticagrelor: a review of its use in adults with acute coronary syndromes.
    Dhillon S
    Am J Cardiovasc Drugs; 2015 Feb; 15(1):51-68. PubMed ID: 25672642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38).
    Kohli P; Udell JA; Murphy SA; Cannon CP; Antman EM; Braunwald E; Wiviott SD
    J Am Coll Cardiol; 2014 Jan; 63(3):225-32. PubMed ID: 24140678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of upstream tirofiban versus downstream tirofiban on myocardial damage and 180-day clinical outcomes in high-risk acute coronary syndromes patients undergoing percutaneous coronary interventions.
    Liu T; Xie Y; Zhou YJ; Li YP; Ma HY; Guo YH; Liu YY; Zhao YX; Shi DM
    Chin Med J (Engl); 2009 Aug; 122(15):1732-7. PubMed ID: 19781316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.